Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)

Next Previous
Trial Profile

A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Lixisenatide; Metformin; Sodium-glucose transport protein inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-O Asia Pacific; Lixilan-O-AP
  • Sponsors Sanofi

Most Recent Events

  • 22 Jun 2023 Results of post hoc pooled analysis from LixiLan-O-AP and LixiLan-L-CN ;evaluating the efficacy of iGlarLixi in the Asian Pacific (AP) population with type 2 diabetes (T2D) using derived time-in-ranges calculated from seven-point self-measured blood glucose, published in the Diabetes, Obesity and Metabolism
  • 01 Aug 2022 Primary endpoint has been met (Change in HbA1c) , according to Results published in the Diabetes, Obesity and Metabolism
  • 01 Aug 2022 Results published in the Diabetes, Obesity and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top